Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 9.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,864 shares of the company’s stock after buying an additional 2,587 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $163,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after buying an additional 2,026 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after buying an additional 2,387 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $54,000. San Luis Wealth Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $54,000. Finally, ADG Wealth Management Group LLC acquired a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $55,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Down 1.1%

Shares of Recursion Pharmaceuticals stock opened at $5.64 on Friday. The business has a 50-day moving average of $5.48 and a 200-day moving average of $5.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The company has a market capitalization of $2.29 billion, a PE ratio of -3.17 and a beta of 0.93. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million for the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm’s revenue was up 33.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) earnings per share. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target for the company. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.